Australian Securities and Investments Commission v Citrofresh International Ltd

The Australian Securities and Investments Commission brought proceedings against Citrofresh International Ltd and its director, Mr Narain. The Commission sought various remedies, including pecuniary penalties and disqualification from managing corporations for Mr Narain, for contraventions of certain sections of the Corporations Act 2001 (Cth). The case centred on the scientific basis of claims made by CIL regarding the efficacy of their product, Citrofresh, in controlling infectious diseases such as HIV.

The primary legal issues were whether Mr Narain contravened s 180(1) of the Corporations Act 2001 (Cth) by not exercising the requisite degree of care and diligence in his role as a director, and whether the claims made by CIL about Citrofresh were scientifically substantiated. This involved assessing the evidence provided by Professor Steven Wesselingh, an expert in infectious diseases, who examined the scientific reports related to Citrofresh. The court had to determine if the reports provided a scientific basis for the claims made by CIL and if Mr Narain's conduct warranted the sought penalties.

In its reasoning, the court found that the scientific evidence did not support the claims made by CIL about Citrofresh. Professor Wesselingh testified that Citrofresh could act as a moderately effective disinfectant but did not offer a novel or innovative solution for disease control. As a result, the claims made by CIL lacked a scientific basis. The court also considered Mr Narain's role in authorising the conduct that led to the contraventions. While the court recognised the importance of the claims made, it found insufficient evidence to substantiate them scientifically. Consequently, the court dismissed the application against Mr Narain and ordered the Commission to pay his costs.